Clinical Roundup “Lock-and-key” chemistry platform may keep therapeutic drugs inactive until they reach a tumor, Syracuse-led study finds February 27, 2026Vol.52 No.08
Clinical Roundup Renal and cardiovascular risks persist decades after testicular cancer treatment February 27, 2026Vol.52 No.08
Clinical Roundup Androgen receptor alterations in bloodwork linked to poorer outcomes across therapies treating metastatic prostate cancer February 27, 2026Vol.52 No.08
Clinical Roundup Exercise during chemotherapy for breast cancer improves quality of life, Sylvester-led study finds February 27, 2026Vol.52 No.08
Clinical Roundup Follicular lymphoma may be curable with chemoimmunotherapy combo, data from 15-year trial suggests February 27, 2026Vol.52 No.08
Clinical Roundup ARPA-H opens first interventional clinical trials to outpace cancer in real time February 20, 2026Vol.52 No.07
Clinical Roundup Cancer cells’ ability to adapt could yield new treatment approaches, NYU-led study finds February 20, 2026Vol.52 No.07
Clinical Roundup NCCN guidelines detail fundamental differences between pediatric and adult cancers February 20, 2026Vol.52 No.07
Clinical Roundup Findings from Cincinnati Children’s study could make immune checkpoint inhibitors safer February 20, 2026Vol.52 No.07
Clinical Roundup Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer February 20, 2026Vol.52 No.07
